VSTM5 Antibody

What is VSTM5 and why is it significant for research?

VSTM5 is a cell adhesion-like molecule belonging to the immunoglobulin (Ig) superfamily that serves dual functions in neuronal development and immune regulation. In neuroscience, VSTM5 regulates neuronal morphogenesis and migration during brain development, promoting dendritic protrusions that later develop into dendritic spines . In immunology, VSTM5 functions as a novel immune checkpoint that inhibits T-cell proliferation, induces T-cell apoptosis, and promotes regulatory T cell generation . Its evolutionary conservation from zebrafish to humans suggests fundamental biological importance . The protein's involvement in both neuronal development and immune modulation makes it an intriguing target for researchers studying neurodevelopmental disorders, neuroinflammation, and autoimmune diseases.

What is the cellular localization pattern of VSTM5?

VSTM5 is primarily expressed in the central nervous system (CNS), with particularly high expression in the brain and spinal cord . Within neurons, properly glycosylated VSTM5 localizes predominantly to the plasma membrane, especially at membrane edges where it induces membrane protrusions . When N-glycosylation is disrupted (either through tunicamycin treatment or mutation of glycosylation sites), VSTM5 becomes trapped in the perinuclear region and co-localizes with endoplasmic reticulum markers like protein disulfide isomerase (PDI) . In immunohistochemistry studies of human brain tissue, VSTM5 staining is specifically localized to neuronal cell bodies . This pattern of expression suggests that VSTM5 antibodies should be validated for specific neuronal staining patterns when used for immunocytochemistry or immunohistochemistry applications.

What methods can be used to confirm VSTM5 antibody specificity?

To confirm VSTM5 antibody specificity, researchers should employ multiple validation approaches:

• Positive and negative control tissues/cells: Compare staining between tissues known to express VSTM5 (brain, spinal cord) versus tissues with minimal expression .

• Knockdown/knockout validation: Use siRNA knockdown of VSTM5 (targeting nucleotides 695-715 of mouse Vstm5 cDNA sequence) to demonstrate reduced antibody signal .

• Recombinant protein controls: Test antibody recognition using recombinant VSTM5 protein (such as the extracellular domain aa 29-147 fused to Fc tag) .

• Western blot analysis: Verify detection of the appropriate molecular weight bands - glycosylated VSTM5 appears at approximately 37 kDa (fully matured form) while deglycosylated forms appear at around 20-21 kDa .

• Cell transfection comparisons: Compare antibody staining in VSTM5-transfected versus mock-transfected cells, as demonstrated in flow cytometry validation of commercial antibodies .

These methods provide complementary evidence of antibody specificity and should be reported in publications using VSTM5 antibodies.

How does glycosylation affect VSTM5 detection with antibodies?

Glycosylation significantly impacts VSTM5 detection with antibodies through multiple mechanisms:

• Molecular weight shifts: Fully glycosylated VSTM5 appears at approximately 37 kDa in Western blots, while non-glycosylated forms appear at around 20-21 kDa . Antibodies raised against different epitopes may preferentially detect glycosylated or non-glycosylated forms.

• Epitope masking: N-linked glycans may conceal antibody binding sites, particularly for antibodies targeting the extracellular domain where all four N-glycosylation sites (N43, N87, N101, and N108) are located .

• Protein conformation: Glycosylation affects protein folding and tertiary structure, potentially altering conformational epitopes recognized by certain antibodies.

• Subcellular localization: Non-glycosylated VSTM5 is primarily retained intracellularly, while glycosylated VSTM5 is expressed at the cell surface . This differential localization must be considered when selecting antibodies for specific applications.

To account for these effects, researchers should consider using deglycosylation enzymes (PNGase F) for Western blot applications and select antibodies validated for detecting both glycosylated and non-glycosylated forms when appropriate.

What are the key structural domains of VSTM5 and their implications for antibody selection?

VSTM5 contains several distinct domains that influence antibody selection strategy:

For cell surface detection (flow cytometry, non-permeabilized ICC), antibodies targeting the extracellular Ig-like V-set domain are necessary . For total protein detection (Western blot, permeabilized ICC), antibodies targeting either domain may work, though C-terminal antibodies avoid potential glycosylation interference . Commercial antibodies are available for both domains, with many raised against the C-terminal region to avoid glycosylation interference .

How can researchers effectively study VSTM5's dual roles in neuronal development and immune regulation?

Investigating VSTM5's dual functionality requires specialized methodological approaches:

• Tissue-specific knockdown/knockout models:

  • For neuronal studies: Use in utero electroporation with shRNA (target sequence: 5'-GCCGTGGCTGTGGTGCTAATC-3') for localized knockdown

  • For immune studies: Generate conditional knockout models specific to T-cell lineages

• Domain-specific mutants:

  • Create chimeric proteins with domain swaps between VSTM5 and related proteins (VISTA, TIGIT) to identify functional domains

  • Generate glycosylation site mutants (N43A, N87A, N101A, N108A) to distinguish roles of different glycosylation sites

• Functional assays:

  • Neuronal function: Analyze dendritic complexity, filopodia formation, and neuronal migration

  • Immune function: Measure T-cell proliferation, cytokine production, and regulatory T-cell induction in the presence of VSTM5.Ig fusion proteins

• Cross-disciplinary approaches:

  • Investigate neuroimmune interactions using co-culture systems with neurons and immune cells

  • Employ multi-omics approaches (transcriptomics, proteomics) to identify shared signaling pathways

These complementary approaches can help delineate the context-specific functions of VSTM5 and identify potential overlapping mechanisms between neuronal and immune functions.

What are the optimal conditions for detecting endogenous VSTM5 using immunohistochemistry?

Detecting endogenous VSTM5 by immunohistochemistry requires careful optimization:

• Tissue preparation:

  • For frozen sections: Fix tissues briefly (4% paraformaldehyde, 10-15 minutes) to preserve membrane protein structure

  • For paraffin-embedded sections: Use heat-induced epitope retrieval with basic pH buffer (Antigen Retrieval Reagent-Basic)

• Antibody selection and dilution:

  • Use antibodies validated specifically for IHC applications

  • Test multiple antibody concentrations (starting recommendation: 3 μg/mL)

• Detection system optimization:

  • For low endogenous expression: Employ signal amplification systems like HRP-polymer detection

  • Use DAB (3,3'-diaminobenzidine) as chromogen for bright field detection

• Controls and counterstaining:

  • Include positive controls (hippocampus, cortex) where VSTM5 is known to be expressed

  • Use appropriate counterstains (hematoxylin for nuclei) to provide cellular context

  • Include immunizing peptide blocking controls to verify specificity

• Signal interpretation:

  • Look for specific neuronal cell body staining pattern

  • Compare with known mRNA expression patterns from qRT-PCR data of brain subregions

These optimized conditions help ensure specific detection of endogenous VSTM5 protein while minimizing background staining.

How can VSTM5 antibodies be used to study neuronal morphology and migration?

VSTM5 antibodies enable detailed investigation of neuronal morphology and migration through several advanced techniques:

• Time-lapse imaging with live-cell labeling:

  • Conjugate VSTM5 antibodies targeting the extracellular domain with pH-sensitive fluorophores (pHluorin) to monitor surface expression dynamics during neuronal migration

  • Use non-perturbing antibody fragments (Fab) to avoid crosslinking and artificial clustering

• Super-resolution microscopy:

  • Employ STORM or PALM imaging with appropriate fluorophore-conjugated antibodies (Alexa Fluor 647) to map VSTM5 distribution in dendritic filopodia at nanoscale resolution

  • Combine with other markers of dendritic structures to correlate VSTM5 localization with morphological changes

• Correlative electron microscopy:

  • Use immunogold labeling with VSTM5 antibodies to precisely localize the protein at the ultrastructural level in dendritic protrusions

  • Combine with cryo-electron tomography for 3D visualization of membrane dynamics

• In utero electroporation followed by immunostaining:

  • After manipulating VSTM5 expression through in utero electroporation, use VSTM5 antibodies to confirm expression patterns and analyze effects on neuronal migration

  • Combine with EdU labeling to correlate VSTM5 expression with cell birth dates and migration timing

These approaches leverage VSTM5 antibodies to connect molecular mechanisms to cellular phenotypes in developing neurons.

What methodological approaches can be used to study VSTM5's role as an immune checkpoint?

To investigate VSTM5's immune checkpoint functions, several specialized methodological approaches using antibodies are recommended:

• T-cell functional assays:

  • Use plate-bound or soluble VSTM5 antibodies to crosslink and activate/inhibit VSTM5 signaling

  • Measure T-cell proliferation (CFSE dilution assay), cytokine production (ELISA/ELISpot), and apoptosis (Annexin V staining) in response to antibody-mediated VSTM5 engagement

• Regulatory T-cell induction studies:

  • Culture naïve T cells with VSTM5 antibodies or VSTM5.Ig fusion proteins

  • Analyze Treg induction by assessing Foxp3 expression using flow cytometry

  • Test induced Tregs in suppression assays to confirm functionality

• In vivo models of oral tolerance:

  • Administer VSTM5.Ig fusion proteins to ovalbumin (OVA)-fed mice

  • Use antibodies to analyze T-cell populations for markers of clonal deletion

  • Measure cell-mediated and antibody responses to assess tolerance induction

• Blocking antibody studies:

  • Generate or obtain VSTM5-blocking antibodies

  • Test effects on autoimmune disease models to determine therapeutic potential

  • Compare effects to established immune checkpoint blockers (anti-PD-1, anti-CTLA-4)

• Receptor identification:

  • Use VSTM5 antibodies in immunoprecipitation followed by mass spectrometry to identify potential binding partners/receptors

  • Confirm interactions using surface plasmon resonance with purified proteins

These methodologies can help elucidate VSTM5's mechanisms of action in immune regulation and identify potential therapeutic applications.

What are common challenges in detecting VSTM5 by Western blot and how can they be addressed?

Detection of VSTM5 by Western blot presents several challenges that can be methodically addressed:

• Multiple banding patterns due to glycosylation:

  • Challenge: VSTM5 appears as multiple bands between 20-37 kDa due to variable glycosylation

  • Solution: Include PNGase F treatment controls to determine which bands represent glycosylated forms

  • Interpretation: Fully mature (glycosylated) VSTM5 appears at ~37 kDa, while deglycosylated forms appear at ~20-21 kDa

• Low endogenous expression levels:

  • Challenge: Endogenous VSTM5 may be difficult to detect in some tissues

  • Solution: Enrich membrane fractions through ultracentrifugation; use high-sensitivity detection systems (ECL Prime/Femto); increase protein loading (50-100 μg)

  • Validation: Include recombinant VSTM5 protein as positive control

• Sample preparation issues:

  • Challenge: Membrane proteins can aggregate during heating

  • Solution: Avoid prolonged boiling; incubate samples at 37°C for 30 minutes or 70°C for 10 minutes in SDS sample buffer

  • Optimization: Test different detergents (NP-40, CHAPS, DDM) for optimal solubilization

• Antibody sensitivity and specificity:

  • Challenge: Different antibodies may preferentially detect specific forms of VSTM5

  • Solution: Test multiple antibodies targeting different epitopes; include transfection controls expressing VSTM5 with epitope tags (1D4, GFP)

  • Verification: Use VSTM5 knockdown samples as negative controls

Following these targeted approaches will improve detection reliability and interpretability of VSTM5 Western blot results.

How can researchers optimize flow cytometry protocols for VSTM5 detection?

Optimizing flow cytometry for VSTM5 detection requires careful attention to several methodological details:

• Sample preparation considerations:

  • Use gentle enzymatic dissociation methods for brain tissue (papain rather than trypsin) to preserve surface epitopes

  • For cell lines, avoid harsh fixation protocols that might alter extracellular domain conformation

• Antibody selection and titration:

  • Choose antibodies specifically validated for flow cytometry applications

  • Perform antibody titration (serial dilutions from 0.1-10 μg/mL) to determine optimal concentration

  • Consider directly conjugated antibodies (Alexa Fluor 488, 647) to minimize background

• Controls and validation approach:

  • Include FMO (fluorescence minus one) controls for multicolor panels

  • Use VSTM5-transfected vs. mock-transfected cells as positive and negative controls

  • Set quadrant markers based on appropriate isotype controls

• Improved detection strategies:

  • For low-expressing samples, employ signal amplification systems

  • When analyzing glycosylation effects, consider parallel samples with and without tunicamycin treatment

  • For co-expression studies, carefully select fluorophore combinations to minimize spectral overlap

• Data analysis recommendations:

  • Gate on single, viable cells before analyzing VSTM5 expression

  • Consider bimodal expression patterns that may represent different glycosylation states

  • Analyze median fluorescence intensity rather than just percent positive cells

This methodical approach will enhance the reliability and sensitivity of VSTM5 detection by flow cytometry in various experimental contexts.

What emerging technologies might advance our understanding of VSTM5 function?

Several cutting-edge technologies show promise for elucidating VSTM5 functions across different contexts:

• CRISPR-based approaches:

  • CRISPRi/CRISPRa for temporal control of VSTM5 expression

  • Base editors to introduce specific glycosylation site mutations without full knockout

  • CRISPR screening to identify genes functionally related to VSTM5 in neuronal and immune contexts

• Advanced imaging technologies:

  • Lattice light-sheet microscopy to monitor VSTM5 dynamics in live neurons during morphogenesis

  • Expansion microscopy combined with VSTM5 antibody staining for nanoscale localization

  • Multiplexed ion beam imaging (MIBI) for simultaneous detection of VSTM5 and multiple markers in tissue sections

• Single-cell multi-omics:

  • Spatial transcriptomics combined with VSTM5 protein detection to map expression patterns with cellular resolution

  • scATAC-seq to identify regulatory elements controlling context-dependent VSTM5 expression

  • Integrated single-cell proteomics and transcriptomics to correlate VSTM5 protein levels with gene expression

• Structural biology approaches:

  • Cryo-EM of VSTM5 in complex with potential binding partners

  • Hydrogen-deuterium exchange mass spectrometry to map conformational changes upon ligand binding

  • AlphaFold-based predictions combined with experimental validation to understand structure-function relationships

These emerging technologies can provide unprecedented insights into VSTM5's dual roles in neuronal development and immune regulation.

How might VSTM5 antibodies contribute to understanding neurological and autoimmune diseases?

VSTM5 antibodies hold significant potential for advancing our understanding of both neurological and autoimmune diseases:

• Neurodevelopmental disorders:

  • Use VSTM5 antibodies to assess protein expression and localization in postmortem brain samples from patients with autism spectrum disorders, schizophrenia, and intellectual disabilities

  • Correlate VSTM5 expression patterns with neuronal morphology abnormalities using quantitative image analysis

  • Investigate VSTM5 as a biomarker for disorders involving aberrant neuronal migration or morphogenesis

• Autoimmune diseases:

  • Analyze VSTM5 expression in immune cells from patients with autoimmune disorders like multiple sclerosis, rheumatoid arthritis, and type 1 diabetes

  • Develop blocking or agonistic antibodies targeting VSTM5 as potential therapeutic agents for autoimmune conditions

  • Explore VSTM5's role in promoting oral tolerance as a therapeutic strategy for food allergies and inflammatory bowel diseases

• Neuroimmune interface disorders:

  • Study VSTM5 expression at the blood-brain barrier during neuroinflammation

  • Investigate potential roles in microglial function and neuroinflammatory responses

  • Develop conjugated antibodies for targeted delivery of therapeutics to VSTM5-expressing cells

• Translational research applications:

  • Use patient-derived induced pluripotent stem cells (iPSCs) differentiated into neurons to study VSTM5's role in disease-specific contexts

  • Develop humanized animal models with patient-specific VSTM5 variants to test therapeutic approaches

These research directions highlight the potential of VSTM5 antibodies as both investigative tools and therapeutic agents in complex human diseases.